Santhera obtains exclusive license agreement for Vamorolone

Schellenberg Wittmer advised Santhera Pharmaceuticals regarding an exclusive license agreement for the Greater China Region with Sperogenix Therapeutics, a China-based company specialising in orphan diseases.  

Under this agreement, Sperogenix will in-license the drug candidate Vamorolone for Duchenne muscular dystrophy and other rare disease indications for a total consideration of up to USD 124 million, including a double-digit upfront cash compensation and DMD-related US-regulatory milestone payments amounting to a combined USD 20 million, as well as further double-digit royalties on net sales. 

Schellenberg Wittmer’s team was led by partner Philipp Groz (IP/life sciences, pictured) and comprised Of counsel Peter Picht (IP/life sciences), partner Michael Nordin (tax), and partner Marcel Jakob (corporate/m&a). 

FabioAdmin

SHARE